Peptide Reference Desk
Liraglutide vs Semaglutide: compare the peptide designs before the headlines
Liraglutide and semaglutide are GLP-1 peptide analogues with different structural modifications, formulations and evidence records.
Same receptor class, different peptide designs
Liraglutide and semaglutide are acylated GLP-1 analogues designed for albumin association and longer exposure than native GLP-1. Their amino-acid substitutions and lipid-linker designs differ, so one sequence or impurity profile cannot stand in for the other.
Brand names are not molecule names
Victoza and Saxenda are liraglutide product records. Ozempic, Wegovy and Rybelsus are semaglutide product records. Indication, route, formulation and jurisdiction belong beside—not inside—the molecular identity field.
| Comparison layer | Use this source |
|---|---|
| Structure | Primary chemistry or regulator quality record |
| Approved use | Current jurisdiction-specific label |
| Trial outcome | Matched head-to-head trial where available |
| Research lot | Lot-linked LC-MS, peptide map and impurity data |
Do not compare isolated percentages
Trial populations, duration, formulation, estimand and missing-data handling can change headline results. A clean archive keeps those fields visible and does not convert an approved-drug comparison into research-material or personal-use guidance.
Verify with primary records
Use the primary paper, current regulator label or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not the evidence itself.